With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...

MMS, an award-winning, data-focused clinical research organization (CRO), announced today its acquisition of Exploristics, a leading biostatistics and data science company based in Belfast, Northern ...

Wide-moat GE HealthCare, or GEHC, is a top three global leader in the medical imaging market. It has a firmly established footprint in hospitals and health networks around the world, and it is ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

The Nifty index opened on a negative note, faced heavy selling pressure in the first half, but later witnessed recovery and ...